Latest Ratios: P/E Ratio -1.7x · EV/EBITDA N/A · ROE -145.7%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $131M | $61M | $87M | $640M | $459M | $866M | $3.4B | — | — |
| Enterprise Value | $119M | $49M | $87M | $635M | $420M | $503M | $3.0B | — | — |
| P/E Ratio → | -1.70 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 2905.75 | — | — |
| P/B Ratio | 2.00 | 2.33 | 0.77 | 3.37 | 1.74 | 2.39 | 7.99 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 2538.39 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 9.1% | 9.1% | 9.0% |
| Operating Margin | — | — | — | — | — | — | -3694.0% | -400.0% | -662.0% |
| Net Profit Margin | — | — | — | — | — | — | -3869.7% | -401.2% | -664.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -145.7% | -145.7% | -88.9% | -71.0% | -39.4% | -21.1% | -21.3% | -433.4% | -150.0% |
| ROA | -98.3% | -98.3% | -69.1% | -58.6% | -36.0% | -20.5% | -20.5% | -176.2% | -123.0% |
| ROIC | -122.0% | -122.0% | -71.8% | -62.4% | -84.9% | -50537.3% | — | — | -1149.3% |
| ROCE | -127.0% | -127.0% | -84.8% | -70.3% | -39.6% | -21.0% | -20.1% | -256.1% | -147.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.15 | 0.09 | 0.04 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.43 | -0.01 | -0.03 | -0.15 | -1.00 | -1.01 | — | -0.90 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -62.48 | -62.48 | -76.99 | -101.75 | -517.56 | -6420.85 | -53.84 | -913.71 | — |
Net cash position: cash ($16M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.07 | 2.07 | 7.26 | 5.24 | 9.57 | 24.00 | 70.28 | 1.97 | 5.45 |
| Quick Ratio | 2.07 | 2.07 | 7.26 | 5.24 | 9.57 | 24.00 | 70.28 | 1.97 | 5.45 |
| Cash Ratio | 1.82 | 1.82 | 6.91 | 5.08 | 9.40 | 23.78 | 69.99 | 1.81 | 4.41 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | 0.45 | 0.19 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | 40.79 | 164.58 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $54M | $52M | $43M | $41M | $40M | $40M | $22M | $22M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALXO stock.
ALX Oncology Holdings Inc.'s current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
ALX Oncology Holdings Inc.'s return on equity (ROE) is -145.7%. The historical average is -121.3%.
Based on historical data, ALX Oncology Holdings Inc. is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Dependence on external equity funding
Metrics are mathematically derived from official filings.
Book Value Premium Despite Losses
ALXO trades at a P/B of 2.40 with a P/E of -0.61 as reported, implying the market prices the pipeline well above the reported equity base despite a cumulative operating loss exceeding $200M over the period shown.
A negative P/E is not meaningful for valuation, so the 2.40 price-to-book multiple is the more informative anchor here. It suggests investors are assigning value to clinical assets and optionality that do not appear on the balance sheet, which warrants further investigation into the pipeline's probability of success. Without forward estimates or EV-based multiples, a relative valuation against own history or peers is limited by the absence of comparable earnings or EBITDA.
Persistently Negative Returns Narrowing
Based on ALXO's reported figures, ROIC improved from -26.0% in 2025Q1 to -10.9% in 2026Q2, though returns remained deeply negative across all ten quarters shown, peaking at -85.2% in 2025Q4.
The trajectory reflects a shrinking loss base rather than any improvement in capital productivity, since the company generates no reported revenue to earn a return on. The sharp deterioration in 2025Q4, when ROE fell to -64.6%, appears linked to a contraction in equity rather than a change in operating economics. Investors should monitor whether returns stabilize as the equity base is rebuilt through issuance.
Low Debt Masks Equity Dependence
As reported in financial statements, ALXO's debt-to-equity ratio sits at 0.07 in 2026Q2 with interest coverage of -63.27, reflecting negative operating earnings rather than any meaningful debt service burden.
The low leverage ratio suggests the company is funded almost entirely by equity, so the absence of debt pressure should not be read as financial strength. Interest coverage is negative because operating income is negative, which means the coverage metric carries little diagnostic value here. The more relevant risk is the recurring need to raise equity to fund operations.
Liquidity Ratios Mask Thin Runway
Based on reported figures, ALXO's current ratio of 9.71 in 2026Q2 appears strong, yet cash of $22.7M against free cash flow of roughly -$34.8M suggests the liquidity cushion covers less than one quarter of burn.
The elevated current ratio is driven by the composition of current assets and does not capture the pace of cash consumption. Against quarterly cash outflows of this magnitude, the liquidity position appears highly dependent on near-term capital raises. Under a severe stress scenario where equity markets close, the current ratio offers little reassurance about operational continuity.
P/B Overstates Asset Backing
The most commonly misapplied metric for a pre-revenue biotech is the price-to-book ratio, which may look like asset coverage but reflects capitalized equity raised rather than tangible earning assets.
For a clinical-stage company, book value largely reflects cash contributed by shareholders and is being consumed by R&D spending, so a 2.40 P/B does not indicate downside protection. A more useful alternative is cash runway measured against projected burn, combined with the probability-weighted value of the pipeline. Investors should treat P/B as a measure of market-assigned optionality rather than asset security.